<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368320">
  <stage>Registered</stage>
  <submitdate>7/04/2015</submitdate>
  <approvaldate>23/04/2015</approvaldate>
  <actrnumber>ACTRN12615000376549</actrnumber>
  <trial_identification>
    <studytitle>Low Dose Atomoxetine in Cardiovascular Disease: A Pilot Study</studytitle>
    <scientifictitle>Effect of low dose Atomoxetine on stress/anxiety levels and cardiovascular risk in patients with hypertension, hypercholesterolemia, diabetes or other cardiovascular disease. </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hypertension</healthcondition>
    <healthcondition>hypercholesterolaemia</healthcondition>
    <healthcondition>diabetes</healthcondition>
    <healthcondition>Stress/anxiety</healthcondition>
    <healthcondition>Overweight/obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral capsule of Atomoxetine Slow Release 3mg taken once daily for 8 weeks. Compliance will be monitored by drug capsule return. Followed by 6 weeks of the same schedule during which time the field will be randomised with a placebo.  </interventions>
    <comparator>Microcellulose capsule placebo </comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Stress/anxiety levels; Proportion of participants with a reduction in stress/anxiety; measured by Depression Anxiety Stress Scales (DASS) &amp; Spielberger Questionnaire.</outcome>
      <timepoint>18 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cardiovascular risk (this is a composite secondary outcome); Proportion of participants with a reduction in weight (kg measured by scales), blood pressure (mmHg measured on an automatic sphygmomanometer), blood cholesterol (serum assay) and glucose (serum assay).</outcome>
      <timepoint>18 weeks </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>currently prescribed medication to treat hypertension, hypercholesterolaemia or diabetes; or have previously suffered an arterial clinical event such as angina, acute myocardial infarction, transient ischemic event, stroke or retinal infarct/haemorrhage; and have a body mass index of greater than 25; and elevated DASS sub scale score (stress &gt; 4, anxiety &gt; 4 or depression &gt; 4) </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>unstable physical illness, clinical and/or questionnaire evidence of major psychiatric disorder and/or patients currently on psychotropic medication, a DASS score &gt; 21, patients with atrial fibrillation or blood pressure &gt; 170/110</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>4/05/2015</anticipatedstartdate>
    <actualstartdate>14/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>19/08/2015</actualenddate>
    <samplesize>20</samplesize>
    <actualsamplesize>2</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Simon Dimmitt</primarysponsorname>
    <primarysponsoraddress>Dr Simon Dimmitt Pty Ltd
Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA  6007</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Professor Simon Dimmitt</fundingname>
      <fundingaddress>Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA  6007</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the pilot study is to establish whether low dose Atomoxetine can be clinically effective in reducing stress/anxiety, have a favourable effects on cardiovascular risk, by not increasing and possibly reducing weight, along with blood pressure, blood cholesterol and glucose.

The plan is to recruit 20 clinically stable patients for a 4 week "run-in" to establish a clear baseline, then prescribe Atomoxetine for 8 weeks. In consenting patients a further 6 weeks of double blind placebo v active will follow. All participants will be evaluated with a full history and physical examination. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St John of God Health Care Human Research Ethics Committee</ethicname>
      <ethicaddress>12 Salvado Rd 
SUBIACO   WA  6008</ethicaddress>
      <ethicapprovaldate>22/10/2014</ethicapprovaldate>
      <hrec>732</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Simon Dimmitt</name>
      <address>Dr Simon Dimmitt Pty Ltd
Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA 6007</address>
      <phone>+61 8 6380 9580</phone>
      <fax />
      <email>sdimmitt@bigpond.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Alicia Moran</name>
      <address>Dr Simon Dimmitt Pty Ltd
Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA 6007</address>
      <phone>+61 8 6380 9585</phone>
      <fax />
      <email>alicia@achf.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Alicia Moran</name>
      <address>Dr Simon Dimmitt Pty Ltd
Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA 6007</address>
      <phone>+61 8 6380 9585</phone>
      <fax />
      <email>alicia@achf.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Alicia Moran</name>
      <address>Suite 3 10 McCourt St 
WEST LEEDERVILLE  WA 6007</address>
      <phone />
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>